Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $22.

August 29, 2024 | 9:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals and maintained a price target of $22, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $22 by Needham suggests positive sentiment and confidence in Avadel Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price as it reinforces investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100